Related Experiment Video
Updated: Sep 4, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
A natural halogenated fluoride adenosine analog 5'-fluorodeoxy adenosine induced anticolon cancer activity in vivo
Long Ma1, Taohua Liu1, Yingying Lu1
1State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, National and Local United Engineering Lab of Metabolic Control Fermentation Technology, China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, China.
Abstract:
Adenosine (ADO) and its analogs have been introduced into the anticancer clinical trials, especial for the ADO derivatives with fluoride. The biosynthesis of fluorinase produces a fluorine-containing ADO analog 5'-fluorodeoxy adenosine (5'-FDA). The toxicity and application of 5'-FDA has not been evaluated, which limits the application of ADO analogs. In order to study its potential mechanism, we carried out the following experiments. In our research, 5'-FDA displayed good antitumor activity in colon cancer cells and two colon cancer models. As a result, 5'-FDA concentration-dependently inhibited the proliferation, migration, and invasion in colon cancer cells through its proapoptosis and cell cycle arrest pathway. Furthermore, 5'-FDA inhibited the growth of colon cancer and its pulmonary metastasis in CT26 inbred mice without affecting their body weight. It was found that 5'-FDA remarkably increased the protein levels of Caspase 3 and cleaved-Caspase 9 and decreased Cyclin A2 and CDK2 via the regulation of p53 signaling pathway, and increased the protein levels of Caspase 8 and cleaved-Caspase 8 which participated in apoptosis pathway. All in all, 5'-FDA displayed excellent therapeutic effects on colon cancer and its pulmonary metastasis. We believed that our study provided a theoretical basis for further preclinical research of 5'-FDA in the treatment of cancer.
Insights
5'-fluorodeoxy adenosine (5'-FDA), a novel adenosine analog, demonstrates significant antitumor effects against colon cancer. This compound effectively inhibits cancer cell proliferation, migration, and invasion, while also reducing metastasis in preclinical models.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Adenosine (ADO) analogs, particularly fluorinated derivatives, are emerging as promising anticancer agents.
- 5 -fluorodeoxy adenosine (5 -FDA), produced by fluorinase, is a novel ADO analog with uncharacterized toxicity and therapeutic potential.
- Limited understanding of 5 -FDA's mechanism hinders the clinical application of ADO analogs in cancer therapy.
Purpose of the Study:
- To evaluate the antitumor activity and underlying mechanisms of 5 -FDA in colon cancer.
- To investigate the effects of 5 -FDA on colon cancer cell proliferation, migration, invasion, and apoptosis.
- To assess the efficacy of 5 -FDA in a preclinical model of colon cancer and its pulmonary metastasis.
Main Methods:
- In vitro studies on colon cancer cell lines to assess proliferation, migration, and invasion.
- In vivo studies using CT26 inbred mice to evaluate antitumor activity and metastasis inhibition.
- Western blot analysis to determine the impact of 5 -FDA on key proteins involved in apoptosis and cell cycle regulation, including Caspase 3, Caspase 8, cleaved-Caspase 9, Cyclin A2, CDK2, and p53 signaling pathway components.
Main Results:
- 5 -FDA exhibited concentration-dependent inhibition of colon cancer cell proliferation, migration, and invasion.
- In vivo, 5 -FDA significantly suppressed colon cancer growth and pulmonary metastasis in mice without adverse effects on body weight.
- 5 -FDA treatment led to increased levels of apoptosis markers (Caspase 3, cleaved-Caspase 9, Caspase 8, cleaved-Caspase 8) and decreased levels of cell cycle regulators (Cyclin A2, CDK2) via p53 pathway modulation.
Conclusions:
- 5 -FDA demonstrates potent antitumor activity against colon cancer and its metastasis through apoptosis induction and cell cycle arrest.
- The study provides a strong theoretical foundation for further preclinical development of 5 -FDA as a therapeutic agent for colon cancer.
- 5 -FDA represents a promising novel agent for colon cancer treatment, warranting further investigation.
More Related Videos
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
